In vitro susceptibility of Sarcoptes scabiei var. hominis to 1% topical ivermectin
DOI:
https://doi.org/10.66344/jpad.25.2.2015.86Keywords:
Scabies, Sarcoptes scabiei, mites, ivermectinAbstract
Objective The objective of this study was to measure the in-vitro susceptibility of Sarcoptes scabiei var. hominis to 1% w/v ivermectin.Methods This interventional (quasi-experimental) study was conducted in the OPD, Dermatology Department, Military Hospital, Rawalpindi from January 2013 to July 2013. A total of 40 mites were taken for assay. Extruded mites from every patient were placed in 1% ivermectin w/v over a glass slide. Mites were inspected for leg movements at hourly intervals. Death was declared once all leg movements had ceased. All mites which died within 5 hours were declared susceptible. The mites having active leg movements even after 5 hours of drug application were considered resistant. Results 100% (n=40) of mites died within 5 hours of application of 1% ivermectin, which was significant.Conclusion Topical 1% ivermectin is effective against Sarcoptes scabiei in terms of in vitro susceptibility.ÂReferences
Hicks MI, Elston DM. Scabies. Dermatol Ther. 2009;22:79-92.
Le Cleach L, Chosidow O. Commentary on "Interventions for treating scabies". Evid Based Child Health. 2011;6:1865-6.
Wolf R, Davidovici B. Treatment of scabies and pediculosis. Facts and controversies. Clin Dermatol. 2010; 28:511-18.
Christine KC, John R, Steven JS et al. Scabies surveillance, prevention and control. Ann Long Term Care. 2009;17:31-5.
Walton SF, Currie BJ. Problems in diagnosing scabies, global disease in human and animal populations. Clin Microbiol Rev. 2007;20:268-79.
Anwar IM, Rizvi SDA, Dilnawaz M et al. Comparison of in-vitro susceptibility of Sarcoptes scabiei var. hominis to 5% permethrin and 1% lindane. PAFMJ. In press 2014.
Pasay C, Arlian L, Morgan M et al. High-resolution melt analysis for the detection of a mutation associated with permethrin resistance in a population of scabies mites. Med Vet Entomol. 2008;22:82-8.
Dourmishev AL, Dourmishev LA, Schwartz RA. Ivermectin: pharmacology and application in dermatology. Int J Dermatol. 2005;44:981-8.
Walton SF, Myerscough MR, Currie BJ. Studies in vitro on the relative efficacy of current acaricides for Sarcoptes scabiei var. hominis. Trans R Soc Trop Med Hyg. 2000;94:92-6.
Mounsey KE, Holt DC, McCarthy J et al. Scabies: molecular perspectives and therapeutic implications in the face of emerging drug resistance. Future Microbiol. 2008;3:57-66.
Rizvi SDA, Iftikhar N, Batool F. Effectiveness of oral ivermectin for eradicating infesting mites in patients of scabies. J Pak Assoc Dermatol. 2011;21:87-92.
Ranjkesh MR, Naghili B, Goldust M, Rezaee E. The efficacy of permethrin 5% vs. oral ivermectin for the treatment of scabies. Ann Parasitol. 2013;59:189-94.
Bachewar NP, Thawani VR, Mali SN et al. Comparison of safety, efficacy, and cost effectiveness of benzyl benzoate, permethrin, and ivermectin in patients of scabies. Indian J Pharmacol. 2009;41:9-14.
Goldust M, Rezaee E, Raghifar R, Hemayat S. Treatment of scabies: the topical ivermectin vs. permethrin 2.5% cream. Ann Parasitol. 2013;59:79-84.
Chhaiya SB, Patel VJ, Dave JN et al. Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. Indian J Dermatol Venereol Leprol. 2012;78:605-10.
Mushtaq A, Khurshid K, Pal SS. Comparison of efficacy and safety of oral ivermectin with topical permethrin in treatment of scabies. J Pak Assoc Dermatol. 2010;20:227-31.
Ribeiro Fde A, Taciro E, Guerra MR, Eckley CA. Oral ivermectin for the treatment and prophylaxis of scabies in prison. J Dermatolog Treat. 2005;16:138-41.
Victoria J, Trujillo R. Topical ivermectin: a new successful treatment for scabies. Pediatr Dermatol. 2001;18:63-5.
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
